IMMUNO30
Immunocore Holdings Plc
A British biotechnology company that engineers a novel class of immunotherapies that harness the body's T cells to fight disease, using its ImmTAX platform. Its first approved medicine, KIMMTRAK, treats a rare eye cancer called uveal melanoma and was the first T-cell receptor therapy ever approved. The company grew out of T-cell research at the University of Oxford, spun out in 2008, and its platform name stands for "Immune Mobilizing Monoclonal TCRs Against X disease."
CONVERTIBLEUnderlying: IMCRCUSIP: 45258DAB1HealthcareGB1 derivative reporter
2.50% Convertible Senior Notes due 2030
No tracked superinvestor held this security as stock in this period — only the derivative positions below reference it.
Derivative Reporters
Investor
Kind
13F reported value
Quantity
Change
